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VI. Counteraction of 
oxidant damage by 
exogenous antioxidants: 
N-(2-mercaptopropionyl)- 
glyciue and catalase 
This study tests the hypothesis that antioxidants administered before 
reoxygenation can reduce oxygen-mediated damage and improve myocar- 
dial performance. Of 25 Duroc-Yorkshire piglets (2 to 3 weeks, 3 to 5 kg) 
five underwent 60 minutes of cardiopulmonary b pass without hypoxemia 
(control group), and five others underwent 30 minutes of hypoxemia on 
cardiopulmonary b pass with a circuit primed with oxygen tension about 
25 mm Hg blood followed by reoxygenation cardiopulmonary b pass (no 
treatment). In vitro studies were performed to obtain the optimal dosage of 
the antioxidants N-(2-mercaptopropionyl)-glycine and and catalase to be 
used in subsequent invivo experimental studies; cardiac homogenates were 
incubated in 0 to 5 mmol/L concentrations of the oxidant -butylhydroper- 
oxide and malondialdehyde production was measured. Fifteen piglets were 
made hypoxemie on cardiopulmonary b pass for 30 minutes, and the 
antioxidants N-(2-mereaptopropionyl)-glycine at either 30 or 80 mg/kg 
body weight or N-(2-mercaptopropionyl)-glycine, 30 mg/kg body Weight, 
and catalase, 50,000 U/kg body weight, were added to the cardiopulmo- 
nary bypass circuit 15 minutes before reoxygenation. Left ventricular 
contractility, which was expressed as end-systolic elastance, was mea- 
sured by conductance catheter before hypoxemia nd after reoxygen- 
ation. Myocardial antioxidant reserve capacity was determined after 
reoxygenation by incubating cardiac homogenates in the oxidant t- 
butylhydroperoxide and measuring subsequent malondialdehyde elution. 
The in vitro bioassay studies showed a dose-dependent reduction of lipid 
peroxidation with N-(2-mercaptopropionyl)-glycine, With maximal benefits 
of a 40% decrease and malondialdehyde elaboration occurring with N-(2- 
mereaptopropionyl)-glycine and catalase compared with untreated car- 
diac homogenates. Cardiopulmonary b pass (no hypoxemia) caused no 
oxidant damage or changes in contractile function after cardiopulmo- 
nary bypass. Reoxygenation without treatment raised conjugated iene 
levels 57%,* lowered antioxidant reserve capacity 51%,* and was 
associated with only 38%* recovery of contractile function (p < 0.05 vs 
control). In contrast, reatment with antioxidants avoided lipid peroxidation, 
maintained antioxidant reserve capacity, and resulted in a dose-dependent 
improvement in left ventricular contractility with complete recovery occur- 
ring in N-(2-mercaptopropionyl)-glyeine and atalase-treated piglets (*p < 
0.05 vs no treatment). This study confirms the occurrence of hypoxemie/ 
reoxygenation i jury in immature hearts placed on cardiopulmonary 
bypass and shows that biochemical and functional damage can be 
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counteracted by adding antioxidants to the cardiopulmonary bypass priming fluid. 
Contractile function improved in a dose-dependent manner, and oxygen-mediated 
damage could be avoided by mercaptopropionyl glycine/catalase treatment. In vitro 
studies were helpful to determine drug dosages to be used in in vivo experiments and 
may be useful to reduce the number of whole animal experiments required to develop 
optimal dosage regimens. (J THORAC CARDIOVASC SURG 1995;110:1212-20) 
A growing body of experimental 1' 2and clinical 3' 4 
evidence indicates that the cyanotic immature 
heart is susceptible to oxygen-mediated injury that 
occurs when molecular oxygen is restored. This 
sequence occurs when cardiopulmonary bypass 
(CPB) is initiated in cyanotic subjects, and we 
confirmed this in immature, hypoxemic intact piglets 
by showing that reoxygenation injury occurred inde- 
pendent of the methods of producing hypoxemia 
and reoxygenation, s The mechanisms of injury ap- 
pear to relate to hypoxemic reduction of endoge- 
nous antioxidants, coupled with the inability to 
detoxify the burst of oxygen free radicals that fol- 
lows reoxygenation. 6 Hydroxyl ion [.OH] is the most 
cytotoxic of the different species of reactive oxygen 
metabolites (hydrogen peroxide [H202], -OH and 
superoxide anion [O2-1) that accentuate the chain 
reaction of lipid peroxidation that follows reoxygen- 
ation 7 and further educe antioxidant reserve capac- 
ity.8, 9 Antioxidants limit oxygen-mediated damage 
in studies of reperfusion after myocardial isch- 
emial0, 11 and reoxygenation after in vitro hypox- 
emia, 12 but the salutary effects of antioxidants in in 
vivo hypoxemic onditions are relatively unestab- 
lished. 
This study was undertaken to test the potential 
salutary effect of N-(2-mercaptopropionyl)-glycine, 
an -OH scavenger, and catalase, an H202 scavenger, 
in reducing reoxygenation injury in reoxygenation f 
the infantile cyanotic piglet undergoing CPB. The 
findings show that (1) antioxidants reduce reoxygen- 
ation injury in a dose-dependent fashion both in 
vitro and in vivo; (2) in vitro bioassay studies are 
helpful to determine optimal in vivo dosage; and (3) 
superior results occur when antioxidant therapy is 
directed against both .OH and H20 2. 
Material and methods 
Preparation. Twenty-five immature, 2- to 3-week-old 
Yorkshire-Duroc piglets (3 to 5 kg) were premedicated 
with 0.5 mg/kg diazepam intramuscularly, anesthetized 
with 30 mg/kg pentobarbital intraperitoneally followed by 
5 mg/kg intravenously each hour, and the lungs ventilated 
on a volume-limited respirator (Servo 900D, Siemens- 
Elema, Solna, Sweden) via a tracheostomy. All animals 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences, published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
The experimental preparation, including cannulation 
for CPB and for monitoring and blood samples, was 
carried out as previously described, s 
Measurements. Hemodynamic measurements were 
made before the start of hypoxemia (control) and 15 and 
30 minutes after CPB was discontinued. 
Blood samples for the determination of conjugated 
dienes from coronary sinus blood were taken before the 
start of CPB (control), 5 minutes after hypoxemia, at the 
end of hypoxemia, 5 minutes after reoxygenation, before 
the discontinuation of CPB (30 minutes of reoxygen- 
ation), and at the end of the 30-minute observation 
period. 
Arterial blood gas, electrolyte, and hemoglobin mea- 
surements were made by a blood gas system (Blood Gas 
System 288, Ciba-Corning, Medfield, Mass.). Final bio- 
chemical measurements were made immediately after 
final evaluation of cardiac mechanical function by taking 
transmural left ventricular (LV) biopsy samples after 
arresting the heart with a 4°C cold blood cardioplegic 
solution (30 mEq KCI) to stop metabolism and placing 
them in liquid nitrogen for subsequent analysis. 
LV performance was evaluated by inscribing end-sys- 
tolic pressure volume relationships using a LV five- 
electrode conductance catheter (Webster Laboratories, 
Baldwin Park, Calif.) inserted through the LV apex, 
connected to a Sigma 5-DF Signal conditioner processor 
(Leycom, Oegstgeest, The Netherlands). 13 A series of 
declining LV pressure-volume loops was obtained by vena 
cava occlusion during a 7-second apnea. The end-systolic 
pressure volume/dimension relationship was analyzed by a 
user-interactive ideographics program "Spectrum ''14 on 
a 386/33 mHz IBM PC. Data were expressed as end- 
systolic elastance (Ees). 
Cardiac output was determined by duplicate 1 ml 
injections of 4 ° C cold saline solution into the right atrium. 
The thermodilution probe was placed in the main pulmo- 
nary artery and connected to a cardiac output computer 
(Model 9520A, American Edwards Laboratory, Santa 
Ana, Calif.). Results were expressed as stroke work index 
(SWI) in g × m/kg to normalize for body weight. SWI = 
(MAP - LAP) × CO × 0.0136/(heart rate × BW), where 
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Fig. 1. Cardiac antioxidant reserve capacity, expressed as percentage of malondialdehyde production in 
myocardial homogenates incubated in 2 mmol/L t-butylhydroperoxide (hatched line 100%, no treatment). 
Note: (1) significant reduction of malondialdehyde elution by incubation with malondialdehyde, catalase, 
or both, (2) absence of effect with SOD; see text for explanation. MDA, Malondialdehyde; t-BHP, 
t-butylhydroperoxide; MPG, N-(2-mercaptopropionyl)-glycine. 
pressure, CO is cardiac output in milliliters per minute, 
HR is heart rate, and BW is body weight in kilograms. 
Systemic vascular esistance index (SVRI) was deter- 
mined by the following equation: SVRI (ram Hg • min • 
m1-1 • kg) = (MAP - CVP) (mm Hg) • CO 1 (ml/ 
min). BW (kg) where CVP is central venous pressure. 
Conjugated iene levels (a marker of lipid peroxida- 
tion) were determined from samples of coronary sinus 
blood as described by Lefnesky and coworkers. 15 
Antioxidant reserve capacity was measured by the 
method of Godin and coworkers 16 to determine vulnera- 
bility of hypoxemic and reoxygenation myocardium to 
subsequent oxidant stress. Myocardial homogenates were 
exposed to 0 to 5 mmol/L t-butylhydroperoxide for 30 
minutes at 37 ° C with subsequent measure of thiobarbitu- 
ric acid-reactive substance. Absorbance 532 nm of the 
organic phase is measured against a reaction blank. Data 
were expressed as nanomoles malondialdehyde p r gram 
protein. 
Each heart was examined postmortem to ensure satis- 
factory ligation of the ductus arteriosus and the absence of 
a patent foramen ovale and to inspect for macroscopic 
damage to abdominal and thoracic structures. 
In vitro studies 
An in vitro bioassay analysis was performed to poten- 
tially reduce the number of experiments needed to deter- 
mine dose-relation responses in the in vivo model. Myo- 
cardial homogenates were incubated with different 
concentrations of the antioxidants superoxide dismutase 
(SOD), N-(2-mercaptopropionyl)-glycine, and catalase to 
determine the dosage that reduced malondialdehyde 
elaboration maximally on exposure to the oxidant t- 
butylhydroperoxide. This oxidant concentration was 
selected because it was the minimum concentration that 
produced significant differences between groups in our 
previous studies of normal and hypoxemic/reoxygen- 
ated tissue, 5
In vivo studies 
Control (no hypoxemia). Five piglets underwent CPB at 
oxygen tension (Po2) about 400 mm Hg for I hour without 
hypoxemia. 
Experimental (hypoxemia and reoxygenation CPB). 
Twenty piglets were placed on CPB with the extracorpo- 
real circuit primed with hypoxemic blood (Po 2 about 25 + 
2 mm Hg). This hypoxemic level was achieved by adding 
N 2 to the gas mixture. Hypoxemia was maintained for 30 
minutes, followed by reoxygenation on CPB for 30 min- 
utes at Po 2 about 400 mm Hg. 
No TREATMENT. Five piglets underwent 30 minutes of 
hypoxemia on CPB as described previously, followed by 30 
minutes of reoxygenation o  CPB (no treatment). 
ANTIOXIDANT TREATMENT. In 10 piglets N-(2-mercapto- 
propionyl)-glycine was added to the CPB circuit 15 min- 
utes before reoxygenation. The dose was 30 mg/kg in five 
piglets and 80 g/kg in five others. 
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Fig. 2. Plasma conjugated diene levels in coronary sinus blood. Note: high levels of this marker of lipid 
peroxidation throughout reoxygenation i  untreated piglets (no treatment) compared with normal 
conjugated diene levels when antioxidants are added to CPB prime. 
In five piglets N-(2-mercaptopropionyl)-glycine (80 
mg/kg body weight) plus catalase (50,000 U/kg body 
weight) were added to the CPB circuit 15 minutes before 
the start of reoxygenation. 
Final biochemical and functional measurements were 
made 30 minutes after CPB observation. 
Statistics. Data were analyzed with the use of the 
StatView V2.0 program (Abacus Concepts Inc., Berkeley, 
Calif.) on a Macintosh IIci computer (Apple, Inc., Cuper- 
tino, Calif.). Analysis of variance was used for intergroup 
comparison, and the paired Student  test was used for 
comparison of variables within experimental groups. The 
relationship between functional impairment (percent Ees) 
and lipid peroxidation (CDs) was tested by linear regres- 
sion analysis. Differences were considered significant at 
the probability level of p < 0.05. Group data were 
expressed as mean plus or minus standard error of the 
mean. 
Results 
In vitro studies 
Malondialdehyde elution in untreated myocardial 
homogenates incubated with 2 mmol/L t-butylhy- 
droperoxide was considered to reflect maximum 
oxidant damage from this oxidant or 100%. SOD did 
not depress malondialdehyde production, whereas 
N-(2-mercaptopropionyl)-glycine was protective in a 
dose-dependent fashion (Fig. 1), with maximum 
inhibition of malondialdehyde occurring when 1 
mmol N-(2-mercaptopropionyl)-glycine was com- 
bined with catalase, 933 units (9 < 0.05). 
In vivo studies 
Biochemical. Reoxygenation caused a 57% in- 
crease in coronary sinus conjugated iene levels 
compared with prehypoxemic control levels (9 < 
0.05, Fig. 2), whereas conjugated dienes remained at 
control levels in all treated piglets. Reoxygenation 
caused a 51% reduction in antioxidant reserve ca- 
pacity in untreated piglets, whereas antioxidant re- 
serve capacity remained within control levels in all 
the piglets receiving antioxidants, with a trend to- 
ward the lowest levels when N-(2-mercaptopropio- 
nyl)-glycine and catalase were combined (Fig. 3,p < 
0.05). 
Hemodynamics. Cardiac Ees recovered com- 
pletely in nonhypoxemic piglets undergoing CPB for 
60 minutes, whereas Ees was restored to only 38% 
of control levels (9 < 0.05) after hypoxemia/reoxy- 
genation in untreated piglets (no treatment, Fig. 4). 
Recovery improved to 60% and 81% respectively, in
a dose-dependent fashion when N-(2-mercaptopro- 
pionyl)-glycine was added to the pump prime at 
30 and 80 mg/kg and returned to 101% of control 
1216 Ihnken et al. 
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Fig. 3. Cardiac antioxidant reserve capacity expressed asproduction of malondialdehyde after incubation 
with 5 mmol/L antioxidant t-butylhydroperoxide. Note: severely reduced antioxidant reserve capacity (high 
malondialdehyde production i untreated animals (no treatment) after hypoxemia and reoxygenation a d 
restoration tocontrol levels by antioxidant treatment. MDA, Malondialdehyde; MPG, N-(2-mercaptopro- 
pionyl)-glycine. 
values when N-(2-mercaptopropionyl)-glycine and 
catalase were combined (p < 0.05 vs untreated 
piglets). 
Discussion 
This study provides data to confirm the occur- 
rence of a biochemical nd functional reoxygenation 
injury that is avoided by antioxidant treatment. 
Supplementation f the CPB prime with the .OH 
and HaO 2 scavengers (N-(2-mercaptopropionyl)- 
glycine and catalase) had the same favorable ffects 
on lipid peroxidation and oxidant reserve capacity 
and functional recovery that occur when these oxi- 
dants are given intravenously before reoxygen- 
ation. 17 Our in vivo findings of the dose-dependent 
benefits of antioxidants quantified by the in vitro 
studies infer that bioassay systems may be useful to 
determine optimal in vivo dosage regimens. 
The experimental model of subjecting immature 
piglets to hypoxemia/reoxygenation on CPB avoids 
ischemic hanges that follow ventilator hypoxemia. 5 
Acute asphyxia (i.e., ventilator hypoxemia) produces 
consistent hemodynamic deterioration that often 
leads to premature institution of CPB, 18 thereby 
preventing imposition of a standard interval and 
magnitude of oxidant stress. The additional advan- 
tages of the in vivo model are described elsewhere 19
together with the limitations caused by the absence 
of compensatory adaptations of chronic cyanosis. 
These limitations notwithstanding, the biochemical 
and functional changes produced by reoxygenation 
parallel alterations in isolated hearts 8'9 and hypox- 
emic patients undergoing reoxygenation CPB. 3' 4 
The potential oxygen-mediated damaging effects of 
CPB were present in all subjects; these included 
activation of leukocytes, 2° the arachidonic path- 
way, al and abnormalities in xanthine metabolism. 22 
Oxidant damage occurred only in untreated piglets 
that did not receive antioxidant treatment and were 
absent when 1 hour of CPB was imposed without 
either hypoxemia or antioxidants. 
The adverse ffects of the hypoxemia/reoxygen- 
ation process have been described previously 8' 9, 23 
and mimic those of ischemia/reperfusion, z4 Our 
current in vivo findings are consonant with (1) 
reduced in vitro myocardial endogenous antioxidant 
depletion during hypoxemia nd further lowering 
during reoxygenation s and (2) evidence of lipid 
peroxidation (malondialdehyde production) after 
reoxygenation developing coincident with enzymatic 
cell damage (creatine kinase release) and myocar- 
dial stunning characterized bydecreased contractile 
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Fig. 4. LV contractility expressed aspercentage r covery of Ees 30 minutes after CPB was discontinued. 
Note: severely depressed function after hypoxemia/reoxygenation in untreated animals (no treatment) in
contrast to dose-related improvement after treatment with N-(2-mercaptopropionyl)-glycine and ormal 
postbypass function after N-(2-mercaptopropionyl)-glycine and catalase (N-(2-mercaptopropionyl)-glycine 
and catalase). 
recovery.9, as. 26 The predominance of oxidant dam- 
age appears to occur with reoxygenation, because 
hypoxemia does not cause lipid peroxidation; con- 
jugated diene levels remained normal during Po 2 
about 25 mm Hg perfusion on CPB (Fig. 2) but 
expends endogenous antioxidants (i.e., SOD and 
glutathione). Consequently, the natural barriers to 
oxidant damage with reintroduction of molecular 
oxygen become depleted and lipid peroxidation 
(conjugated iene production) that causes subse- 
quent myocardial functional damage follows reoxy- 
genation. 9 Exogenous replenishment of antioxidants 
bolsters this otherwise xpended natural defense 
against oxidant injury, but our studies do not define 
the sources of reactive oxygen intermediates (i.e., 
catecholamines, 27 prostaglandin pathways, 28cardiac 
mitochondria, 27 or endothelium 29) or the site of 
action (i.e., cytosol or membrane) of the antioxi- 
dants. The answers to the aforementioned questions 
require future studies to determine the sources of 
cytotoxic O 2 species and site-directed antioxidants 
to define their foci of action. 
Bioassay studies were conducted on normal myo- 
cardial homogenates incubated with varying concen- 
trations of the oxidant -butylhydroperoxide to de- 
termine if these in vitro and relatively inexpensive 
analyses would furnish data on antioxidant dosage 
that could be transferred to the more expense in 
vivo model and therefore limit the number of whole 
animal studies that were needed. Oxidant damage is
inevitable in in vitro studies because the myocar- 
dium contains a finite concentration f endogenous 
antioxidants, whereas an unlimited amount of oxi- 
dant can be added to overwhelm natural defense 
barriers. Consequently, all tissues will exhibit evi- 
dence of oxidant damage when the oxidant chal- 
lenge overwhelms the endogenous antioxidant de- 
fense mechanisms. Resultant malondialdehyde 
levels are related inversely to reserve capacity, as 
shown in Fig. 1. The 100% value indicates how much 
malondialdehyde is produced in the presence of 
endogenous antioxidants and how exogenous addi- 
tives reduce lipid peroxidation. We evaluated SOD 
to test the system, and it did not reduce lipid 
peroxidation; the oxidant -butylhydroperoxide was 
added exogenously, and SOD is not involved. N-(2- 
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Table. Hemodynamics before, during, and after CPB 
MPG MPG 
Control No Rx (30 mg) (80 mg) MPG + CAT 
Cardia£ index (ml/min/kg) 
Start 114 +_ 18 112 ± 7 119 ± 14 133 ± 22 136 ± 8 
15 min CPB 96 _+ i? 112 _+ 11 131 +_ 19 120 -+ 32 96 ± 8 
30 min CPB 92 ± 9 i26 ± 21 123 _+ 22 88 ± 11 79 -+ 8* 
60 min CPB 90 _+ 8 111 ± 20 87 ± 8 76 ± 9 55 ± 14' 
30 min off CPB 82 ± 8 74 _+ 7 69 ± 8 79 -+ 9 132 ± 24? 
Stroke work index (g. m/kg) 
Start 0.47 _+ 0.06 0.49 _+ 0.06 0.47 _+ 0.06 0.42 ± 0.09 0.49 ± 0.06 
30 min off CPB 0.26 _+ 0.04 0.26 _+ 0.03 0.21 _+ 0.04 0.24 _+ 0.06 0.49 -- 0.17 
Heart rate (beats/rain) 
Start 186 202 ± 4 202 ± 9 206 ± 13 190 -+ 10 
30 min off CPB 196 212 ± 7 188 ± 12 205 ± 10 176 ± 10" 
Mean aortic pressure (mm Hg) 
Start 70±5 69±3 65±2 58±5 54_+2 
15 rain CPB 63 _+ 4 54 _+ 2 52 ± 2 52 ± 2 56 ± 8 
30 rain CPB 62 _+ 3 56 +_ 4 55 -+ 4 53 _+ 2 62 ± 3 
60 min CPB 65 ± 4 59 ± 3 52 ± 2 52 ± 2 58 -+ 2 
30 min off CPB 59 ± 4 60 ± 7 55 ± 7 49 _+ 4 52 _+ 4 
MPG, N:(2-mercaptopropionyl)-glycine. 
*p < 0.05 vs no treatment. 
tp < 0.05 vs all other groups. 
mercaptopropionyl)-glycine is an .OH scavenger 
and exerted a dose-dependent reduction in oxidant 
damage. The additional effects of catalase are as- 
cribed to its capacity to alter the peroxidatic reac- 
tion as described by Chance and colleagues. 3° 
N-(2-mercaptopropionyl)-glycine a d catalase 
were the only antioxidants ested in these studies 
and produced near-complete avoidance of reoxy- 
genation injury under the imposed experimental 
conditions. Other antioxidants (i.e., deferoxamine, 31 
CoQ10, 32 allopurinoly or agents directed at other 
sources of oxygen injury (i.e., white cells, z° arachi- 
donic acid metabolism 28) may provide comparable 
protection. N-(2-mercaptopropionyl)-glycine is an 
• OH scavenger that may be effective in both the 
classic Haber-Weiss pathway and the newly de- 
scribed L-arginine-nitric oxide pathway of oxidative 
injury, because N-(2-mercaptopropionyl)-glycine 
also scavenges the toxic intermediate p roxynitrite 
(OONO-). 34 Hydroxyl radical (.OH) is more cyto- 
toxic than 0 2 ,3s but there is no satisfactory expla- 
nation how extracellularly formed .OH reaches the 
cellular target, because it reacts within a few Ang- 
stroms of its site of formation. 36Conversely, OONO- 
is sufficiently stable to diffuse several cell diameters 
before being protonated to yield .OH 36 and may 
therefore be a more immediate source of reoxygen- 
ation injury in vivo. However, this is speculative, 
because our observations only quantify evidence of 
lipid peroxidation and myocardial dysfunction. 
The benefits of antioxidant pretreatment have 
been stressed previously by Dhaliwal and col- 
leagues 9 and Bolli and coworkers 1°in both ischemic 
and hypoxemic preparations. The concentrations 
found effective in our bioassay studies are compara- 
ble with those reported by Zimmer and Evers 37 in 
the isolated rat heart model exposed to hypoxemia/ 
reoxygenation. The total 80 mg/kg in vivo dose was 
increased over that used in our previous intravenous 
studies 17 to overcome the dilutional effects intro- 
duced by the priming volume of the CPB circuit. 
The resultant intravascular concentrations were 
comparable with those found cardioprotective by
Mitsos and colleagues 1° and somewhat higher than 
those reported by Bolli and coworkers 11 in the 
ischemia/reperfusion model. Our previous tudies in 
the ventilator hypoxemia model showed that N-(2- 
mercaptopropionyl)-glycine and catalase were car- 
dioprotective ither as pretreatment (intravenous 
infusion during hypoxemia) or when added to the 
extracorporeal prime to ensure their presence at the 
initiation of reoxygenation. I  the present studies of 
the model of hypoxemia/reoxygenation on bypass, 
adding N-(2-mercaptopropionyl)-glycine and cata- 
lase exerted the dual effect of pretreatment (because 
they were administered during hypoxemia) and en- 
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sured effective concentration i the CPB circuit at 
the initiation of reoxygenation. 
We believe that this study supplies additional 
evidence that reoxygenation i jury occurs during 
initiation of CPB in hypoxemic subjects. The impor- 
tance of considering use of antioxidants i under- 
scored by reports of myocardial depression pro- 
gressing to stunning (absence of aortic pulsations) in 
cyanotic infants placed on extracorporeal mem- 
brane oxygenation for pulmonary disorders causing 
hypoxemia 3 and preischemic tissue biopsy evidence 
of lipid peroxidation and diminished endogenous 
antioxidants in cyanotic hildren placed on CPB for 
correction of tetralogy of Fallot. 3'4 Recognition of 
this potential source of unintended myocardial dam- 
age should allow appropriate preparations to be 
made to counteract it, because both intravenous 
pretreatment and supplementation f the prime of 
the extracorporeal circuit with antioxidants can be 
accomplished readily in the clinical setting. We hope 
that these experimental findings provide a stimulus 
to others to study this issue and test the reproduc- 
ibility of our findings, because it appears that reoxy- 
genation injury is an avoidable complication of CPB 
in hypoxemic subjects. 
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